Rockville, Md. (April 14, 2026) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic, platelet-derived, cellular therapeutics, today announced the publication of new preclinical research demonstrating that its freeze-dried platelet-derived biologic (FDPlts) significantly improved vascular stability and reduced inflammation in a model of traumatic brain injury (TBI).
The study, conducted in collaboration with researchers at the University of California, San Francisco (UCSF) and published in Blood, provides the first evidence that a platelet-derived biologic can promote blood-brain barrier (BBB) repair, reduce intracranial hemorrhage, and modulate neuroinflammation following TBI.
In a murine model of TBI, treatment with FDPlts:
Mechanistic analyses identified activation of the Angiopoietin-1 (Ang1)–Tie2 signaling pathway as a key driver of the observed vascular stabilization and neuroprotective effects.
Expanding Beyond Hemostasis:
“These findings represent a significant step in redefining what platelet-derived therapies can achieve,” said Mike Gaffney, Chief Executive Officer of Cellphire Therapeutics. “This work reinforces our belief that Cellphire’s platform has the potential to address some of the most critical unmet needs in trauma and critical care medicine, including conditions where vascular dysfunction drives outcomes.”
Addressing a Significant Unmet Need:
Traumatic brain injury remains a leading cause of death and disability worldwide, with limited therapeutic options available to address acute complications such as cerebral edema and intracranial hemorrhage.
For access to the full research article, use the below link:
A Dried Platelet-Derived Biologic for Blood-Brain Barrier Repair and Hemorrhage Control Following TBI in Mice | Blood | American Society of Hematology
Forward Looking Statements:
This press release contains forward-looking statements regarding the development and potential applications of Cellphire’s product candidates. These statements are based on current expectations and are subject to risks and uncertainties, including the results of future preclinical and clinical studies.
About Cellphire Therapeutics
Cellphire Therapeutics, Inc.’s vision: No one should die from controllable hemorrhage. Cellphire is a private, clinical stage biotechnology company developing next-generation, allogeneic, platelet-derived therapies. Cellphire has a portfolio of platelet-derived biologics including two assets in clinical development: its late-stage biologic CLPH-511, a cryopreserved platelet (CPP) therapy with extended shelf life, and CLPH-211, part of the FPH® family of freeze-dried, platelet-derived hemostatic agents. Once approved, Cellphire’s differentiated technologies will address significant unmet health system and medical needs across various clinical settings including acute bleeding associated with surgery, trauma and traumatic brain injury. For more information, visit www.Cellphire.com.
Robert Woods
VP, Operations
RWoods@Cellphire.com